CLINICAL TRIALS PROFILE FOR PANCRELIPASE
✉ Email this page to a colleague
All Clinical Trials for pancrelipase
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00006063 ↗ | Randomized Study of Pancrelipase With Bicarbonate (PANCRECARB) Capsules in Reducing Steatorrhea in Patients With Cystic Fibrosis | Completed | Indiana University School of Medicine | N/A | 1999-07-01 | OBJECTIVES: I. Compare the efficacy of enteric coated pancrelipase with bicarbonate (PANCRECARB) capsules versus the patient's usual enteric coated pancreatic enzyme without bicarbonate in decreasing fecal fat and nitrogen losses in patients with cystic fibrosis. |
| NCT00006063 ↗ | Randomized Study of Pancrelipase With Bicarbonate (PANCRECARB) Capsules in Reducing Steatorrhea in Patients With Cystic Fibrosis | Completed | National Center for Research Resources (NCRR) | N/A | 1999-07-01 | OBJECTIVES: I. Compare the efficacy of enteric coated pancrelipase with bicarbonate (PANCRECARB) capsules versus the patient's usual enteric coated pancreatic enzyme without bicarbonate in decreasing fecal fat and nitrogen losses in patients with cystic fibrosis. |
| NCT00217204 ↗ | An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption | Completed | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Phase 2 | 2005-07-01 | The purpose of this study is to evaluate the effectiveness and safety of PANCREASE MT (pancrelipase microtablets) to improve steatorrhea (excessive excretion of fat in feces) in infants and toddlers with cystic fibrosis who have pancreatic insufficiency, and to assess whether the consistency of the microtablets is acceptable for swallowing in infants and toddlers |
| NCT00266721 ↗ | Efficacy of Pancrelipase on Postprandial Belching and Bloating. | Completed | Solvay Pharmaceuticals | Phase 3 | 2000-01-01 | The hypothesis of this study is that the administration of pancrelipase with meals will benefit symptoms of post-prandial bloating, pain and eructation. |
| NCT00414908 ↗ | A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy | Completed | Solvay Pharmaceuticals | Phase 3 | 2007-10-01 | This study assessed the effect of pancrelipase delayed release capsules on fat and nitrogen absorption in subjects with PEI due to Chronic Pancreatitis and Pancreatectomy. There was a run-in with a 5-day of single-blind placebo treatment, followed by a 7-day Double-blind period and a 6-month Open-Label Follow-up. |
| NCT00432861 ↗ | Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis | Completed | Digestive Care, Inc. | Phase 3 | 2007-01-01 | The primary objective of this study is to determine if PANCRECARB® MS-16 (pancrelipase) is safe and effective in reducing steatorrhea (as measured by 72-hour stool fat determinations) in children and adults with cystic fibrosis and pancreatic insufficiency. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for pancrelipase
Condition Name
Clinical Trial Locations for pancrelipase
Trials by Country
Clinical Trial Progress for pancrelipase
Clinical Trial Phase
Clinical Trial Sponsors for pancrelipase
Sponsor Name
